Imophoron, founded in 2017 and led by CEO Frederic Garzoni, develops the ADDomer next-generation rapid-response vaccine platform based on a self-assembling thermotolerant protein. The ADDomer permits rapid insertion of large numbers of peptide and protein epitopes in a single particle, intended for next-generation vaccines against present and future infectious diseases including potential ‘Disease X’. The company secured GBP 4m in funding to continue development of its self-assembling protein sub-units and the ADDomer platform. Planned work includes demonstrating safety, efficacy and immune response in animal models across three viruses: lead candidate RSV, Chikungunya and COVID-19. Specific activities include pre-clinical efficacy, immunogenicity and safety packages for regulatory interactions for RSV, manufacturing research batches and establishment of cell lines and cell banks. For COVID-19 and Chikungunya the company will design and select potential candidates and complete pre-clinical efficacy studies, and it will design and implement a scale-up manufacturing strategy and perform necessary toxicology assays.

Total raised

$5M

Funding rounds

1

Latest round

Equity

Latest activity

Oct 2021